WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET family proteins, used to induce cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcription; it also suppresses tumor growth in enzalutamide-resistant castration-resistant prostate cancer (CRPC) xenograft models.